Skip to main content
News & Press Releases

Imagin Medical Reports Research Study Progress

By 17 July 2018August 11th, 2022No Comments

Vancouver, B.C. and Boston, MA, July, 17, 2018 – Imagin Medical (CSE: IME) (OTCQB:IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) announced todayfavorable results in the 10-subject investigator-sponsored research study being conducted at the University of Rochester Medical Center using the i/Blue Imaging System (the “URMC Research Study”), an important step in the development of a commercially-viable product.

In the URMC Research Study, fluorescence was successfully demonstrated in 15 minutes, confirming that the i/Blue Imaging System will potentially allow physicians to “see” bladder cancer significantly faster than the full hour or more required by currently available imaging technology.

“While a backorder on certain component parts needed to make system adjustments during the URMC Research Study caused some delay, we are obviously very pleased with the outcome,” said Jim Hutchens, Imagin’s President and CEO. “This is an exciting time. We believe that the i/Blue Imaging System holds great promise for improving physicians’ ability to detect cancer and visualize the surgical field where endoscopes are used. To that end, we look forward to updating our stakeholders as we progress.”

Information gathered from the URMC Research Study is being used to help optimize Imagin’s i/Blue technology to further the development of a commercially-viable device system in preparation for the Company’s planned clinical trials to support its application to the U.S. Food and Drug Administration (“FDA”) for approval to market the i/Blue Imaging System in the United States.

“Imagin is grateful to the University of Rochester Medical Center for initiating and conducting this investigator-sponsored human research study,” commented Pam Papineau, Imagin’s Director of Regulatory and Clinical Affairs. “Imagin was pleased to provide early prototype equipment to assist the investigators in testing the underlying hypothesis that the i/Blue Imaging System can potentionally identify protoporphyrin IX (PpIX) fluorescence associated with bladder cancer lesions in the presence of the contrasting agent, hexaminolevulinate hydrochloride. This project was undertaken prior to the commencement of an FDA application, and provides important insights that will help guide the Company in an FDA-compliant process. Imagin anticipates initiating preliminary discussions with the FDA regarding the i/Blue Imaging System as soon as possible.”

Running parallel to the URMC Research Study, the i/Blue Imaging System design and development has moved forward, incorporating feedback from the study into the system’s optoelectronic functions and features. As previously reported, Optel, Inc., Imagin’s opto-electronic design firm, is working against three phases of development: Proof of Concept, Functional Unit and Verified Unit. Of the three phases, the Proof of Concept phase has now been completed, verifying the performance of the two critical optical modules of the i/Blue Imaging System – the light source module and the imaging module.

Jay Eastman, Ph.D., CEO of Optel, stated, “The lessons learned from the URMC Research Study has provided valuable technical data, clinical insight and physician feedback that is significantly influencing the design of the i/Blue System. All of this information continues to increase our confidence that the miniaturization, imaging quality and cost reduction goals for the i/Blue System important to surgeons performing bladder cancer procedures.”

About Imagin Medical

Imagin is developing powerful new imaging solutions for the detection and visualization of cancer. The Company believes its technology will radically improve physicians’ ability to detect cancer with minimally invasive endoscopes, improving their ability to visualize, identify and remove cancerous cells. Imagin’s initial target market is bladder cancer, the sixth most common cancer in the U.S., and the costliest cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, Imagin’s advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.


Stephen Kilmer, Investor Relations
Telephone: 647-872-4849
Email: [email protected]

Jim Hutchens, President & CEO
Telephone: 833-246-2446
Email: [email protected]